+ T cells will differentiate into effectors that differ in their ability to survive: some will persist as memory cells while the majority will die by apoptosis. Signals given by antigen-presenting cells (APCs) at the time of priming modulate this differential outcome. We have recently shown that, in opposition to dendritic cell (DC), CD40-activated B-(CD40-B) cell vaccination fails to efficiently produce CD8 + memory T cells. Understanding why CD40-B-cell vaccination does not lead to the generation of functional long-lived memory cells is essential to de�ne the signals that should be provided to naïve T cells by APCs. Here we show that CD40-B cells produce very low amount of IL-6 when compared to DCs. However, supplementation with IL-6 during CD40-B-cell vaccination did not improve memory generation. Furthermore, IL-6-de�cient DCs maintained the capacity to promote the formation of functional CD8 + effectors and memory cells. Our results suggest that in APC vaccination models, IL-6 provided by the APCs is dispensable for proper CD8 + T-cell memory generation.
Introduction
e recognition of a foreign antigen (Ag) presented by specialized Ag-presenting cells (APCs) in lymphoid organs by naïve CD8 + T cells leads to their activation, differentiation, and proliferation. is is accompanied by changes in migration properties and gain of effector functions to control the infection. Aer elimination of the pathogen, most (90-95%) of the activated CD8 + effector T cells (Te) die during the contraction phase to reset the system for the next challenge. Importantly, a fraction of the Ag-speci�c Te cells will survive as resting memory T cells (Tm) able to respond quickly to a second Ag encounter.
During acute infection, two subsets of CD8 + effectors, short-lived effector cells (SLECs; CD127 lo and KLRG-1 hi ), and memory precursor effector cells (MPECs; CD127 hi and KLRG-1 lo ) can be identi�ed at the peak of the response [1] [2] [3] [4] [5] [6] . Only MPECs, which represent about 10% of the Agspeci�c population at the peak of the response, survive and further differentiate into Tm cells [1] [2] [3] [4] [5] . However, a different picture emerged in vaccination strategies using Ag-pulsed APCs [2, [7] [8] [9] [10] [11] or Ag plus adjuvant [8, 12] . We and others have shown that CD8 + T-cell response to immunization with TLR-stimulated DCs follows a different course than response to infection [2, [7] [8] [9] [10] . Due to low in�ammation, the majority of CD8
+ Te cells acquire an MPEC phenotype at the peak of the response [2, [7] [8] [9] [10] . ese MPECs are very good effectors endowed with the ability to produce cytokines and kill target cells [10, 11] . Unlike the MPECs that are generated following infection, MPECs obtained following DC vaccination will still undergo a normal contraction phase [7, 8] and thus only a fraction of them will become long-lived Tm cells. Similarly, vaccination with Ag plus adjuvant generates a high proportion of CD127 hi cells (MPECs) at the peak of the response and only a fraction of them will survive as longlived CD8
+ Tm cells [8, 12] . Following vaccination with Ag plus adjuvant, it was shown that high level of expression of IL-6 receptor (R) chain in combination with high level of expression of IL-7R (CD127) better identi�es the MPECs that will further differentiate into Tm cells [12] . is suggests that IL-6 signal might contribute to Tm-cell development.
Until recently, little was known about the potential of other APCs, such as B cells, to induce a CD8 + T-cell response [11, [13] [14] [15] . We and others have shown that CD40-activated B (CD40-B) cells can prime a functional CD8 + T cell response in vivo [11, [13] [14] [15] . We have shown that as for DC vaccination, all effectors acquire a MPEC phenotype following CD40-B-cell immunization [11] . Furthermore, these MPECs have excellent effector functions as measured by their ability to secrete cytokines, kill target cells in vivo and clear a bacterial infection [11] . Although MPECs were generated with CD40-B-cell vaccination, Tm-cell generation was inefficient [11] . erefore, understanding why CD40-B cell vaccination does not lead to the formation of functional long-lived Tm cells is essential to de�ne the signals that should be provided to naïve T cells by APCs to promote efficient Tmcell differentiation. e reported high level of expression of IL-6R by prememory CD8 + T cells [12] suggests that IL-6 may be one of the missing signal.
IL-6 was �rst identi�ed as a B-cell proliferation and differentiation factor [16] . Its high affinity receptor is composed of the IL-6R chain and the common gp30 chain [16] . As many cytokines, IL-6 has pleiotropic action on different cell types of the immune system [16] . Speci�cally, on CD8 + T cells, IL-6 was reported to promote the survival of naïve T cells [17] [18] [19] [20] , to enhance the proliferation of CD8 + T cells following TCR triggering [14, [20] [21] [22] [23] and to synergize with IL-7 or IL-15 to induce Ag-independent proliferation of CD8 + T cells [24] . IL-6 was also shown to contribute to in vivo CD8 + T-cell response. Indeed, maximal in vivo CD8 + T cell proliferation following vaccination with CD40-B cells stimulated via the B cell receptor and TLR7 was dependent on IL-6 production by B cells [14] . Moreover, cytotoxic CD8 + T-cell differentiation was dependent on IL-6 induction by adjuvant in vaccination protocol [25] . Finally, the transfer of CD8 + MPECs into IL-6-de�cient hosts severely impaired the generation of longlived CD8 + Tm cells [12] . ese studies suggest that IL-6 is essential for optimal and complete in vivo response of CD8
e reported in�uences of IL-6 on CD8 + T-cell response lead us to investigate whether IL-6 signal from APCs during priming was necessary to promote the formation of CD8 + Tm cells following APC vaccination. In this paper, we show that CD40-B cells stimulated with LPS produce very low amount of IL-6 when compared to DCs and that supplementation with IL-6 during CD40-B-cell vaccination did not improve their ability to generate CD8 + Tm cells. Furthermore, vaccination with IL-6-de�cient DCs did not impede their ability to promote the formation of functional CD8 + effectors and memory T cells. 
Materials and Methods

B-Cell and DC Cultures.
For B-cell culture, lymphocytes were isolated on a FICOLL gradient from male B6.SJL spleen followed by a 4 days culture on irradiated �broblasts stably transfected with the CD40L cDNA (3T3-CD40L) to generate CD40-B cells [28] . Bone-marrow-derived DCs were generated as previously described [8] . e day before harvesting, lipopolysaccharide (LPS) (1 g/mL) was added to DC and CD40-B-cell cultures. e ovalbumin (OVA 257-264 ) peptide (SIINFEKL) (Midwest biotech) was loaded overnight on DCs (2 g/mL) and B cells (4 g/mL). T-cell response against the male minor histocompatibility antigen HY [29] . Some mice were injected intraperitoneally (i.p) with 500 ng of recombinant mouse IL-6 (R&D Systems). e presence of Te (d4 post-immunization) and Tm (d45 postimmunization) cells was evaluated in the same mouse by sequential removal of super�cial lymph nodes as described previously [8] . Functions of Te (d4) and Tm (d60) were analyzed as previously described with minor modi�cations [8] . Splenocytes were restimulated with 2 g/mL OVA 257-264 peptide in complete RPMI 1640 for 6 h at 37 ∘ C. For the last 3 h, 10 g/mL of brefeldin A (Sigma Aldrich) was added. Te and Tm cells were identi�ed by �ow cytometry as being CD8 + and CD45.2 + .
Immunization and Analysis of T-Cell
Mouse Surgery.
Lymph node removal by surgery was done as described [30] . Brie�y, mice were anesthetised by inhalation of iso�urane (2%, 1L oxygen). Before the surgery, eye ointment was applied to avoid eye dryness and buprenorphine was administered subcutaneously (0.05-0.1 mg/Kg) as an analgesic. To harvest the brachial and the inguinal lymph nodes, a small incision (5 mm) of the skin was made and the lymph nodes were removed using forceps. e incision was closed with one clip (Michel suture clips, 7.5 × 1.75 mm, Harvard Apparatus).
Antibodies, Cytometry
, and ELISA. Anti-CD86 (GL-1), -TNF-(MP6-XT22), and -Bcl-2 (3F11) antibodies were purchased from BD Biosciences. Anti-H-2K b (AF6-88.5), -CD45.2 (104), -CD44 (1M7), -CD8 (53-6.7), -CD19 (6D5), -CD11c (N418), -CD80 (16-10A1), -IL-6R (D7715A7), -CD43 (1B11), -CD62L (MEL-14), and -IL-2 (JES6-5H4) antibodies were purchased from Biolegend. Anti-I-A b (28-16-8S) was purchased from Cedarlane. Anti-CD127 (A7R34), -Eomes (Dan11mag), -KLRG1 (2F1), andgranzyme B (16G6) antibodies were purchased from eBioscience. Anti-Bcl-6 (7D1) antibody was purchased from Santa Cruz Biotechnology. Anti-CXCR3 (220803) antibody was purchased from R&D Systems. Anti-IFN-(XMG1.2) antibody was purchased from Life technologies. OVA peptide loading on K b MHC was measured by staining with the 25-D1.16 Ab [31] followed by staining with a rat anti-mouse IgG1 (A85-1) antibody from BD Biosciences. Cell surface and intracellular stainings for cytokines were performed as previously described [8, 32] . Bcl-6 and Eomes intracellular stainings were performed with the FoxP3 kit from eBioscience. For Bcl-2 staining, cells were stained for 30 minutes in 0.1% saponin (Sigma-Aldrich) and washed twice without saponin before cell surface staining. All stainings were analyzed on a BD FACSCanto I system.
For ELISA, B cells and DCs were cultured as described above. Before harvesting, supernatants were collected and ELISA was performed against IL-6 (Biolegend), according to the manufacturer's protocol.
Statistical Analysis.
Statistical analyses for differences between groups were performed using Mann Whitney test (two experimental groups) or one-way ANOVA followed by Games-Howell posttest (3 experimental groups or more). Data are presented as mean ± standard error of the mean (SEM). All tests were two-sided and was considered statistically signi�cant. * , * * , * * * and NS: non-signi�cant.
Results and Discussion
Expression of IL-6R by CD8
+ T Cells following Vaccination with APCs. Our previous work has shown that vaccination with CD40-B cells matured with LPS and loaded with the OVA peptide leads to the formation of functional CD8 + Te cells but not Tm cells [11] . Although the CD8 + Te cells generated following CD40-B cell vaccination were enriched for MPECs (CD127 hi and KLRG1 lo ), they did not survive the contraction phase [11] . Since high level of IL-6R expression was shown to better identify at the peak of the T-cell response the MPECs that will differentiate into CD8 (Figures 1(a) and 1(b) ), which efficiently generates CD8 + Tm cells. ese results indicate that MPECs generated following CD40-B cell vaccination should be able to respond to IL-6 during the contraction phase of the response. e fact that CD40-B-cell vaccination generates MPECs expressing high levels of both IL-7R (Supplemental Figure 1 and 
IL-6 Supplementation Does Not Enhance CD8
+ Tm-Cell Generation following CD40-B-Cell Vaccination. e reported role of IL-6 in CD8
+ T-cell proliferation and differentiation [12, 14, [20] [21] [22] [23] 25 ] leads us to evaluate if CD40-B cells were providing IL-6 during the priming of naïve CD8 + T cells. IL-6 was quanti�ed in the supernatants obtained at the end of CD40-B-cell and DC cultures. As shown in Figure 1 (c), CD40-B cells produce around 5-fold less IL-6 than DCs. is reduced production of IL-6 might be responsible for the lack of CD8 + Tm-cell generation with CD40-B-cell vaccination.
To test whether the decreased IL-6 production by CD40-B cells was responsible for their inability to induce CD8 + Tm-cell development, we injected IL-6 at the time of CD40-B-cell immunization. e dose of IL-6 was chosen based on previous publications where IL-6 injection had an effect on T-cell response [33, 34] . As shown in Figure 2 , the administration of IL-6 (500 ng) i.p. at the time of OT-I naïve CD8
+ T-cell priming by CD40-B cells did not enhance the generation of CD8 + Te and Tm cells. Furthermore, the effectors generated with or without IL-6 supplementation had a similar phenotype as determined by the expression of CD44, CD127, and Bcl-2 (Supplemental Figure 1) .
IL-6 Is Dispensable for the Generation of CD8
+ Tm Cells following Vaccination with DCs. Since it was possible that the amount administered and the route of injection did not lead to a sufficient IL-6 signals in naïve OT-I T cells, we tested whether IL-6 production by DCs was necessary for the generation of long-lived CD8 + Tm cells. To do so, we generated DCs from the bone marrow of IL-6-de�cient mice. Before using these IL-6-de�cient DCs in our vaccination protocol, we con�rmed that they had a similar phenotype than wild-type DCs following LPS maturation (Supplemental Figure 2) . Furthermore, IL-6-de�cient DCs were equally loaded with the OVA peptide as WT DCs (Supplemental Figure 2) . We then compared the OVA-speci�c CD8 + Tcell response following vaccination with IL-6-de�cient orsufficent DCs. As shown in Figure 3 , a similar frequency and number (not shown) of CD8 + Te and Tm cells were generated following vaccination with WT or IL-6 KO DCs. Furthermore, the yield of CD8 + Tm cells (% of Te cells that developed into Tm cells) was similar in both groups ( Figure  3(b) ). ese results show that IL-6 production by APCs at the priming of naïve CD8 + T cells is not necessary for the generation of CD8 + Te and Tm cells. Several reports have shown that IL-6 can enhance CD8 + T-cell proliferation in vitro [14, [20] [21] [22] [23] [24] and in vivo [14] . However, the use of IL-6-de�cient DCs did not reduce the number of CD8 + Te cells generated. us, it is possible that the basal level of IL-6 present in the host is sufficient for optimal T-cell proliferation or that IL-6 production by DCs is not necessary for maximal 
proliferation of CD8
+ T cells. Moreover, IL-6 production by CD40-B cells stimulated via the BCR and TLR7 was reported to be necessary for the maximal expansion of Ag-speci�c CD8 + T cells following vaccination [14] . us, our results with IL-6 KO DCs suggest that different APC types might produce different cytokines to promote the full expansion of CD8 + T cells. However, in our hands supplementation of IL-6 during CD40-B-cell vaccination did not increase T-cell expansion (Figure 2 ). is might be explained by the use of different stimuli (BCR + TLR7 ligand versus LPS) to mature the CD40B cells that may lead to production of different cytokines.
�.�. �a���na���n ���� �����De���en� DCs �ene�a�es ��n����nal CD8
+ Te and Tm Cells. Since IL-6 was shown to in�u-ence cytotoxic T-cell differentiation [25] , we have carefully evaluated the phenotype and functions of the OVA-speci�c CD8 + Te and Tm cells generated following vaccination with WT or IL-6 KO DCs. As shown in Figure 4 , both types of effectors produce similar amounts of IFN-, TNF-, IL-2, and where IL-6 induction by adjuvant was critical for cytotoxic T-cell differentiation [25] . One possible explanation is that vaccination with fully matured DCs bypassed the needs for IL-6. Altogether our results suggest that IL-6 production by the DCs involved in the priming of naïve CD8 + T cells is dispensable for the proper differentiation of CD8 + Te cells. Although CD8
+ Tm cells were generated following vaccination with IL-6-de�cient DCs, it was important to investigate if the Tm cells generated were fully functional. As shown in Figure 6 , OVA-speci�c CD8 + Tm cells obtained with both WT and IL-6 KO DCs were similarly functional. ey both produced similar amounts of IFN-, IL-2, TNFand granzyme B (Figure 6 ). ese results show that IL-6 production by APCs during priming of naïve CD8 + T cells is also dispensable for the generation of fully functional CD8 + Tm cells.
Our results show that IL-6 production by DCs is dispensable for the generation of fully functional CD8 + Tm cells. Furthermore, they also suggest that the lack of production of IL-6 by CD40-B cells is probably not the explanation for their inability to induce the formation of CD8 + Tm cells. Further studies are required to understand why CD40-B-cell vaccination does not promote the generation of CD8 + Tm cells. Possible explanations include differences in the site of priming, the level of costimulation, the interaction time with T cells, and the production of other soluble mediators such as IL-12 or type I IFNs. e ability of IL-6-de�cient DCs to promote the generation of functional CD8
+ Tm cells indicates that other soluble factors (IL-12 and IL-23) produced by DCs are sufficient to induce the generation of CD8 + Tm cells. Indeed, it was shown by others that vaccination with IL-12 and IL-23 de�cient DCs abrogated CD8
+ Tm-cell development [44] . It is also possible that IL-6 plays a role during CD8
+ Tm-cell differentiation but that it does not have to be produced by the APCs involved in the T cell priming.
In conclusion, we show that the inability of CD40-Bcell vaccination to induce the formation of CD8 + Tm cells is not due to their reduced production of IL-6. Similarly, vaccination with IL-6-de�cient DCs did not impede their ability to promote the formation of functional CD8 + Tm cells. us, IL-6 production by the APCs involved in the priming of naïve CD8 + T cells is dispensable for the formation of CD8 + Tm cells. Furthermore, our results also highlight the various role of IL-6 in different immunization protocol. Vaccination with DC does not rely on IL-6 for the full expansion and differentiation of CD8 + Te cells while IL-6 is necessary when adjuvant is used. 
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